{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 48,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/14",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.46,
        "x": 0.505,
        "y": 0.24
      },
      "kind": "chart",
      "text": "BCVA ETDRS LETTER CHANGE AT WEEK 12 Secondary Endpoint",
      "attrs": {
        "series": [
          {
            "name": "OCS-01",
            "value": 7.6
          },
          {
            "name": "VEHICLE",
            "value": 3.7
          }
        ],
        "chart_type": "bar",
        "x_axis_label": "Treatment Group",
        "y_axis_label": "LS mean (± SE) change in BCVA from baseline (ETDRS letters)"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a45b9ac2-6f26-4131-bc58-c81efff32e77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.46,
        "x": 0.04,
        "y": 0.24
      },
      "kind": "chart",
      "text": "BCVA ETDRS LETTER CHANGE AT WEEK 6 Primary Endpoint",
      "attrs": {
        "series": [
          {
            "name": "OCS-01",
            "value": 7.2
          },
          {
            "name": "VEHICLE",
            "value": 3.1
          }
        ],
        "chart_type": "bar",
        "x_axis_label": "Treatment Group",
        "y_axis_label": "LS mean (± SE) change in BCVA from baseline (ETDRS letters)"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a63529df-e870-4432-9b2c-9b3861894165",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.249,
        "x": 0.723,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis Diamond",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3d682c2-6bac-481e-ba1c-9e1433da0b85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.939,
        "x": 0.028,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "Imputation rules are applied based on a pattern-mixture model approach. BCVA (Best corrected visual acuity); ETDRS (Early Treatment Diabetic Retinopathy Study); ITT (Intention-to-treat). Tadayoni R, et al. A 12-week phase 2/3 double-masked, randomized, multicenter study of OCS-01 OPTIREACH® technology topical dexamethasone eye drops in subjects with diabetic macular edema (DME): efficacy and safety findings. Presented at: EURETINA; 2023.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da374356-b743-4776-9f9c-3cfe402dec78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.87,
        "x": 0.104,
        "y": 0.14
      },
      "kind": "title",
      "text": "7.2-letter gain in BCVA vs baseline at week 6, increasing to 7.6 at week 12",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "822cf173-d95a-404a-9213-3fc2dc0719b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.66,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "5 Key Takeaways From OCS-01 DIAMOND Stage 1",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68f6d81c-409d-4fdc-b59c-74e4fa3bd46c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}